Smither John W
Director at NAMS; Director at GNLX; former officer at ARQT, and 1 more
- Sold, on record
- $8.3M
- Dollars the filings state
- Form 4 sales
- 36
- Latest Sep 4, 2026
- Form 144 notices
- 2
- Proposed sales
- Companies
- 4
- Filed as an executive or holder
Companies
- NAMSNewAmsterdam Pharma Co N.V.Director
- GNLXGENELUX CorpDirector
- ARQTArcutis Biotherapeutics, Inc.former officer
- KYTHERA BIOPHARMACEUTICALS INCChief Financial Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- KYTHERA BIOPHARMACEUTICALS INC148,571 shares
- ARQT19,023 shares
- GNLX12,900 shares
- NAMS1,600 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale ARQTPlan not statedFeb 10, 2021 2021
Sold 2,750 shares at $35.64 ($98k)
Smither John W, Chief Financial Officer
Sold 9.8% of holdings ($996k position)25,198 shares left0.8x usual sizeFiling
- 2 Form 4 sale ARQTPlan not statedMar 1, 2021 +19 days
Sold 773 shares at $34.20 ($26k)
Smither John W, Chief Financial Officer
Sold 3.1% of holdings ($862k position)24,425 shares left0.3x usual sizeFiling
- 3 Form 4 sale ARQTPlan not statedMar 10, 2021 +9 days
Sold 1,750 shares at $32.90 ($58k)
Smither John W, Chief Financial Officer
Sold 3.6% of holdings ($1.6M position)46,321 shares left0.8x usual sizeFiling
- 4 Form 4 sale GNLXNo planSep 13, 2023 +917 days
Sold 900 shares at $20.78 ($19k)
Smither John W, Director
No 10b5-1 planSold 11.5% of holdings ($162k position)6,920 shares leftFirst sale on recordFiling
- 5 Form 144 notice ARQTNoticeMay 17, 2024 +247 days
Filed to sell 1,770 shares ($16k)
Smither John W, former officer
No 10b5-1 planFirst sale on recordFiling
- 6 Form 144 notice ARQTNoticeJun 26, 2024 +40 days
Filed to sell 7,396 shares ($69k)
Smither John W, former officer
No 10b5-1 planFirst sale on recordFiling
- 7 Form 4 sale GNLXNo planJul 1, 2026 +735 days
Sold 12,000 shares at $2.91 ($35k)
Smither John W, Director
No 10b5-1 planSold 11.6% of holdings ($301k position)91,403 shares leftFirst sale on recordFiling
- 8 Form 4 sale NAMSNo planSep 4, 2026 +65 days
Sold 1,600 shares at $25.32 ($41k)
Smither John W, Director
No 10b5-1 planSold 15.4% of holdings ($262k position)8,760 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales and notices (38)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | Sep 9, 2026 | NAMS | Director | Form 4 sale | 1,600 | $41k | 15.4% | No plan | SEC |
| Jul 1, 2026 | Jul 2, 2026 | GNLX | Director | Form 4 sale | 12,000 | $35k | 11.6% | No plan | SEC |
| Jun 26, 2024 | Jun 26, 2024 | ARQT | former officer | Form 144 notice | 7,396 | $69k | Notice | SEC | |
| May 17, 2024 | May 17, 2024 | ARQT | former officer | Form 144 notice | 1,770 | $16k | Notice | SEC | |
| Sep 13, 2023 | Sep 14, 2023 | GNLX | Director | Form 4 sale | 900 | $19k | 11.5% | No plan | SEC |
| Mar 10, 2021 | Mar 11, 2021 | ARQT | Chief Financial Officer | Form 4 sale | 1,750 | $58k | 3.6% | Plan not stated | SEC |
| Mar 1, 2021 | Mar 3, 2021 | ARQT | Chief Financial Officer | Form 4 sale | 773 | $26k | 3.1% | Plan not stated | SEC |
| Feb 10, 2021 | Feb 12, 2021 | ARQT | Chief Financial Officer | Form 4 sale | 2,750 | $98k | 9.8% | Plan not stated | SEC |
| Feb 1, 2021 | Feb 3, 2021 | ARQT | Chief Financial Officer | Form 4 sale | 5,000 | $175k | 16.6% | Plan not stated | SEC |
| Jan 19, 2021 | Jan 21, 2021 | ARQT | Chief Financial Officer | Form 4 sale | 1,750 | $53k | 6.5% | Plan not stated | SEC |
| Dec 14, 2020 | Dec 16, 2020 | ARQT | Chief Financial Officer | Form 4 sale | 5,250 | $158k | 17.2% | Plan not stated | SEC |
| Sep 29, 2020 | Oct 1, 2020 | ARQT | Chief Financial Officer | Form 4 sale | 1,750 | $53k | 6.8% | Plan not stated | SEC |
| Sep 24, 2015 | Sep 24, 2015 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 53,835 | $4M | 94.1% | Unusual | SEC |
| Sep 22, 2015 | Sep 23, 2015 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 6,645 | $498k | 66.4% | Unusual | SEC |
| Jun 25, 2015 | Jun 25, 2015 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 4,600 | $347k | 29.5% | Unusual | SEC |
| Apr 30, 2015 | Apr 30, 2015 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 2,041 | $93k | 11.6% | Plan not stated | SEC |
| Mar 5, 2015 | Mar 5, 2015 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 4,200 | $202k | 25.6% | Unusual | SEC |
| Feb 18, 2015 | Feb 19, 2015 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 2,000 | $82k | 10.9% | Plan not stated | SEC |
| Jan 29, 2015 | Feb 2, 2015 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 1,000 | $38k | 5.2% | Plan not stated | SEC |
| Jan 23, 2015 | Jan 27, 2015 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 3,000 | $107k | 13.4% | Unusual | SEC |
| Dec 22, 2014 | Dec 22, 2014 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 375 | $13k | 2.3% | Plan not stated | SEC |
| Nov 20, 2014 | Nov 20, 2014 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 375 | $13k | 2.3% | Plan not stated | SEC |
| Oct 20, 2014 | Oct 20, 2014 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 375 | $12k | 2.3% | Plan not stated | SEC |
| Sep 22, 2014 | Sep 22, 2014 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 375 | $13k | 2.3% | Plan not stated | SEC |
| Aug 20, 2014 | Aug 20, 2014 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 375 | $13k | 2.3% | Plan not stated | SEC |
| Jul 21, 2014 | Jul 21, 2014 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 375 | $13k | 2.3% | Plan not stated | SEC |
| Jul 2, 2014 | Jul 3, 2014 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 2,250 | $90k | 12.2% | Plan not stated | SEC |
| Jun 20, 2014 | Jun 24, 2014 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 375 | $14k | 2.3% | Plan not stated | SEC |
| May 20, 2014 | May 21, 2014 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 375 | $12k | 2.8% | Plan not stated | SEC |
| Apr 21, 2014 | Apr 21, 2014 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 375 | $14k | 2.8% | Plan not stated | SEC |
| Mar 20, 2014 | Mar 20, 2014 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 1,125 | $49k | 9.9% | Plan not stated | SEC |
| Feb 20, 2014 | Feb 21, 2014 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 2,250 | $112k | 18.1% | Plan not stated | SEC |
| Feb 14, 2014 | Feb 18, 2014 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 1,125 | $56k | 9.9% | Plan not stated | SEC |
| Jan 21, 2014 | Jan 21, 2014 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 1,125 | $48k | 9.9% | Plan not stated | SEC |
| Sep 10, 2013 | Sep 10, 2013 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 40,000 | $1.2M | 100.0% | Unusual | SEC |
| Aug 1, 2013 | Aug 2, 2013 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 10,000 | $268k | 100.0% | Unusual | SEC |
| Jun 17, 2013 | Jun 18, 2013 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 6,000 | $156k | 100.0% | Unusual | SEC |
| May 1, 2013 | May 3, 2013 | KYTHERA BIOPHARMACEUTICALS INC | Chief Financial Officer | Form 4 sale | 4,000 | $96k | 100.0% | Unusual | SEC |